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Abstract
Nucleoside analogue reverse transcriptase inhibitors are an integral component of combination antiretroviral
treatment regimens. However, their ability to inhibit polymerase-c has been associated with several mito-
chondrial toxicities, including potentially life-threatening lactic acidosis. A total of 650 antiretroviral-naive adults
(69% female) initiated combination antiretroviral therapy (cART) and were intensively screened for toxicities
including lactic acidosis as part of a 3-year clinical trial in Botswana. Patients were categorized as no lactic
acidosis symptoms, minor symptoms but lactate <4.4 mmol/liter, and symptoms with lactate ‡4.4 mmol/liter
[moderate to severe symptomatic hyperlactatemia (SH) or lactic acidosis (LA)]. Of 650 participants 111 (17.1%)
developed symptoms and/or laboratory results suggestive of lactic acidosis and had a serum lactate drawn; 97
(87.4%) of these were female. There were 20 events, 13 having SH and 7 with LA; all 20 (100%) were female
(p<0.001). Cox proportional hazard analysis limited to the 451 females revealed that having a higher baseline
BMI was predictive for the development of SH/LA [aHR=1.17 per one-unit increase (1.08–1.25), p<0.0001].
Ordered logistic regression performed among all 650 patients revealed that having a lower baseline hemoglobin
[aOR=1.28 per one-unit decrease (1.1–1.49), p=0.002] and being randomized to d4T/3TC-based cART [aOR=
1.76 relative to ZDV/3TC (1.03–3.01), p=0.04] were predictive of the symptoms and/or the development of SH/
LA. cART-treated women in sub-Saharan Africa, especially those having higher body mass indices, should
receive additional monitoring for SH/LA. Women presently receiving d4T/3TC-based cART in such settings
also warrant more intensive monitoring.
Introduction
N
ucleoside analogue reverse transcriptase inhibi-
tors (NRTIs) are effective antiretroviral therapies for
the treatment of HIV-1-infected adults and are central to
effective combination antiretroviral therapy (cART). NRTIs
continue to be a critical component of ART regimens as
cART is rolled out in resource-limited settings with medi-
cations such as stavudine (d4T) being extensively used due
to its favorable cost and formulation beneﬁts.
1–3 Active in-
tracellular anabolites of approved NRTIs block viral repli-
cation by competing with cellular deoxynucleotide
triphosphates (dNTP) for incorporation into proviral DNA,
andare speciﬁcforHIV-1reversetranscriptase.
4–6 However,
their ability to inhibit human mitochondrial polymerase-c,
resulting in impaired synthesis of mitochondrial enzymes
that generate ATP by oxidative phosphorylation, has been
associated with several long-term mitochondrial toxi-
cities.
4,6,7 These include lactic acidosis, myopathy, pancrea-
titis, peripheral neuropathy, and lipoatrophy.
4 Lactic
acidosis is one of the most serious mitochondrial toxicities
witharecentlypublishedsystematicreviewdocumentingan
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759overall case fatality rate of 48%.
8 Symptomatic cART-treated
patients identiﬁed as having signiﬁcantly elevated serum
lactate concentrations (greater than 10.0 mmol/liter) have a
documented mortality rate of 80%.
9
Higher rates of symptomatic hyperlactatemia (20.2 cases
per 1000 person-years) and lactic acidosis (10.6 cases per 1000
person-years) have been reported among southern African
cART-treated adults,
10 particularly among overweight fe-
males.
10–15Inadditiontofemalesexandobesity,theuseofthe
NRTIs d4T and/or didanosine (ddI), advanced age (greater
than 40 years of age), pregnancy, prolonged cART duration,
reduced creatinine clearance, and advanced immunosup-
pression (baseline CD4
+ cell count values less than 100 cells/
mm
3) have also been shown to be risk factors for the devel-
opment of lactic acidosis.
8–18
The Adult Antiretroviral Treatment and Drug Resistance
(Tshepo) study was an open-label, randomized, factorial
design study conducted at Princess Marina Hospital in
Gaborone, Botswana. Preliminary ﬁndings have shown that
cART-treated adults enrolled in the Tshepo study had higher
than expected rates of lactic acidosis, speciﬁcally among
overweight (body mass indices greater than 25) females.
19
Herein, we report predictive model data of risk factors for
the development of moderate to severe symptomatic hy-
perlactatemia/lactic acidosis for the completed study.
Materials and Methods
Study population
The Botswana cohort consisted of patients enrolled in the
completed Adult Antiretroviral Treatment and Drug Re-
sistance (‘‘Tshepo’’) study between December 1, 2002 and
December 31, 2007.
20 Tshepo was an open-label, randomized,
3·2·2 factorial design study conducted at Princess Marina
Hospital in Gaborone, Botswana evaluating the efﬁcacy,
tolerability, and incidence of drug resistance mutations
among six different ﬁrst-line cART regimens: zidovudine,
lamuvidine, plus nevirapine (ZDV/3TC/NVP); zidovudine,
lamuvidine, plus efavirenz (ZDV/3TC/EFV); zidovudine,
didanosine, plus nevirapine (ZDV/ddI/NVP); zidovudine,
didanosine, plus efavirenz (ZDV/ddI/EFV); stavudine, la-
muvidine, plus nevirapine (d4T/3TC/NVP); and stavudine,
lamuvidine, plus efavirenz (d4T/3TC/EFV). The study also
compared two different adherence strategies: intensiﬁed
adherence arm; standard-of-care plus community-based
supervision (ComDOT) versus standard-of-care (SOC) to
determine the optimal means of promoting adherence among
adults receiving ﬁrst-line cART.
All study participants were followed for 3 years with
monthly scheduled study visits. There were two CD4
+ cell
count strata: (1) study participants either qualiﬁed for cART
based on existing Botswana national antiretroviral (ARV)
treatment guidelines,
21,22 namely, an AIDS-deﬁning illness
and/or CD4
+ cell count £200 cells/mm
3, or they met (2) the
study eligibility criteria of having a CD4
+ cell count between
201 and 350 cells/mm
3 and a corresponding plasma HIV-1
RNA level >55,000 copies/ml, which was consistent with
consensusUnitedStatesadulttreatmentguidelinesatthetime
the study was designed.
The primary endpoints of the original trial were develop-
ment of virologic failure with genotypic drug resistance and
development of treatment-related toxicity, as deﬁned by the
ﬁrst incidence of a grade 3 or higher adverse event. Secondary
endpoints were death for any reason and time to non-
adherence (namely, an estimated adherence of less than 90%).
Primary analyses of efﬁcacy endpoints were performed on an
‘‘intent-to-treat’’ basis.
Inclusion criteria
Inclusion criteria were age 18 or greater; Karnofsky Score
‡50; permanent address within 20km of the study site; pos-
itive HIV-1 parallel ELISAs; CD4
+ cell count of £200 CD4
+
cells/mm
3 or a CD4
+ cell count between 201 and 350 cells/
mm
3 and a plasma HIV-1 viral load >55,000 copies/ml; he-
moglobin ‡8.0g/dl, absolute neutrophil count ‡1.0·10
3/
mm
3, creatinine level less than two times the upper limit of
normal (£200lmol/liter), and serum SGPT (ALT) and SGOT
(AST) values less than ﬁve times the upper limit of normal,
205U/liter and 170U/liter, respectively. Inclusion criteria for
women of child-bearing potential included the following:
nonpregnant, at least 6 months postpartum, and a willingness
to maintain active contraception throughout the duration of
the study.
Exclusion criteria
Exclusion criteria were presumed or conﬁrmed visceral,
but not mucocutaneous, Kaposi’s sarcoma and a diagnosis
of ‡Grade 2 peripheral neuropathy within 1 month of
enrollment.
All enrolled study participants underwent routinely
scheduled safety (toxicity) monitoring. They had compre-
hensive chemistry and hematology specimens drawn as fol-
lows after cART initiation: scheduled comprehensive
chemistry and hematology tests monthly for the ﬁrst 6
months, then every 2 months for the next 6 months (6–12
months following cART initiation), and then every 4 months
for the remainder of the study follow-up (12–36 months fol-
lowing cART initiation). In addition, all patients with any one
or more out-of-range chemistry and/or hematology results
were immediately called in for clinical assessment and con-
ﬁrmatory blood draw.
A serum lactate was immediately drawn on all cART-
treated Tshepo study participants who developed one or
more of the following symptoms and/or laboratory abnor-
malities suggestive of underlying lactatemia: grade 3 or
higher SGPT (ALT) and/or SGOT (AST), grade 3 or higher
LDH; serum bicarbonate level less than 20.0 mmol/liter,
nausea/emesis, increased fatigue, dyspnea, muscle weak-
ness, and/or paralysis of the lower extremities. Venous
plasma lactates were obtained according to the AIDS Clin-
ical Trials Group protocol
23 a n dw e r em e a s u r e db yac o l o r -
imetric assay using the Roche Integra 400 Plus (Roche
Diagnostics, Mannheim, Germany).
Deﬁnitions
Moderate to severe symptomatic hyperlactatemia (SH).
Screened patients found to have a serum lactate level greater
than twice the upper limit of normal (‡4.40 mmol/liter) with
associated symptoms (as described above), and based on
additional laboratory testing (serum bicarbonate and/or ar-
terial/venous pH testing) without evidence of acidosis,
namely having a serum pH>7.35 and/or serum bicarbonate
760 WESTER ET AL.>20 mmol/liter, were diagnosed as having moderate to se-
vere symptomatic hyperlactatemia.
Lactic acidosis (LA). Screened patients found to have a
serum lactate level ‡4.40 mmol/liter with one or more pos-
itive symptoms with evidence of acidosis, namely a serum
pH<7.35 and/or serum bicarbonate less than 20 mmol/liter,
were diagnosed as having lactic acidosis.
Statistical considerations
We analyzed time to moderate to severe symptomatic hy-
perlactatemia (SH) or lactic acidosis (LA) using a Cox pro-
portional hazard model, with the time to the SH or LA event
being determined as thetime of a ﬁrst lactate test result of4.40
mmol/liter or more. Twenty subjects had an event based on
this deﬁnition. Subjects who did not have the event were
censored at the end of the study or time lost to follow-up.
Since SH or LA occurred only in women, we analyzed the risk
for the development of SH/LA only among female Tshepo
study participants (n=451 total). The model included age,
body mass index (BMI), and the nucleoside backbone to
which the study participants were randomized (ZDV/3TC
versus ZDV/ddI versus d4T/3TC) as a priori deﬁned risk
factors. Age and BMI were included as continuous variables.
Missing values of BMI [4 (0.06%) of 650] were imputed using
multiple imputation.
In addition, we analyzed for the presence of clinical
symptoms and/or laboratory abnormalities suggestive of
possible underlying SH/LA (‘‘symptoms’’) and/or having an
SH/LA event (‘‘development of SH/LA’’) in the entire study
population (n=650) using ordered logistic regression. The
outcome had three levels: (1) a subject was never screened for
lactic acidosis (n=539 subjects); (2) a subject was screened
because of suggestive clinical symptoms and/or laboratory
abnormalities, but the laboratory test result never exceeded
4.4 mmol/liter (n=91 subjects); and (3) a subject wasscreened
and the serum lactate result was greater than or equal to 4.4
mmol/liter (n=20subjects). Nucleoside backbone (ZDV/3TC
versus ZDV/ddI versus d4T/3TC), nonnucleoside type (NVP
versus EFV), adherence strata (SOC versus ComDOT), age,
sex, BMI, CD4
+ cell count, viral load (plasma HIV-1 RNA),
and hemoglobin were a priori chosen for inclusion in the or-
dered logistic model. Missing values of BMI (4), viral load (1),
and hemoglobin (13) were imputed using multiple imputa-
tion. The viral load was log10 transformed. Age, BMI, CD4
+
cell count, viral load, and hemoglobin were included as con-
tinuous variables. Nonlinearity was assessed for these vari-
ables using restricted cubic splines; there was no evidence to
suggest nonlinear relationships, so these variables were in-
cluded as linear terms.
p-values less than 0.05 were considered to be statistically
signiﬁcant. Analyses were conducted using SAS statistical
software (version 9.2, SAS Institute, Cary, NC) and R statis-
tical software (version 2.9.0, www.r-project.org). The analysis
code is available at http:/ /biostat.mc.vanderbilt.edu/Archi-
vedAnalyses/LacticAcidosis2011.
This study was approved by the Health Research and De-
velopment Committee of the Botswana Ministry of Health,
the Harvard School of Public Health Human Subjects Com-
mittee, and the Vanderbilt University Institutional Review
Board.
Results
Baseline characteristics
Overall, 650 adults were enrolled, 451 (69.4%) of whom
werefemale.Themedianagewas33years (IQR29–39).Forty-
three percent had advanced WHO clinical disease (Stage 3 or
4) at the time of enrollment. The median CD4
+ of the entire
study population was 199 cells/mm
3 (IQR 136–252). Study
participants had a median baseline hemoglobin level of
11.6g/dl (IQR 10.4–12.9) and median BMI of 21.3 (IQR 19.2–
24.3), with 22% (n=139) having a baseline BMI of >25 and
19% (n=121) having a baseline BMI of <18.5 (Table 1). Of
note, when broken down by sex, 26.4% (119 of 451) of the
females compared to 10.1% (20 of 199) of the males had a
baseline BMI of greater than 25. A higher proportion of males
(69% versus 56%) had normal baseline BMIs (i.e., between
18.5 and 25). A total of 330 (50.8%) patients were enrolled in
the lower CD4
+ stratum (CD4
+ cell count value less than or
equal to 200 cells/mm
3) and 320 (49.2%) patients were en-
rolled in the upper CD4
+ cell count stratum (CD4
+ cell count
value between 201 and 350 cells/mm
3); 325 participants were
randomized to the intensiﬁed adherence (Com-DOT) arm.
Follow-up
Study follow-up was approximately 1774 person-years, with
a median follow-up time of 156 weeks (IQR 156–157). Ninety-
eight percent of all scheduled follow-up visits were attended.
Duringthestudy,54(8.3%)ofthe650enrolledpatientswerelost
to follow-up with regard to primary endpoint information. Of
the 54, 26 (48%) had moved out of the study catchment area, 9
(16.7%) declined further participation, and for 19 (35.2%), no
further information was available despite repeated attempts by
the study team to contact them. The sociodemographic and
clinical characteristics of participants who were lost tofollow-up
did not statistically differ from those who completed the trial.
Moderate to severe symptomatic hyperlactatemia
and lactic acidosis outcomes
During the 3 years of follow-up, 111 study participants had
a total of 208 serum lactate levels drawn during routine
Table 1. Baseline Characteristics
of the Study Population
Characteristic Median [IQR]
Age 33.3 years [28.9–38.7]
Gender 451 female (69.4%)
199 male (30.6%)
CD4
+ cell count (cells/mm
3) 199 [136–252]
£200 cells/mm
3 (lower strata) 330 (50.8%)
201–350 cells/mm
3 (upper strata) 320 (49.2%)
Plasma HIV-1 RNA (copies/ml) 195,000
[70,350–473,750]
Hemoglobin (gr/dl) 11.6 [10.4–12.9]
Body mass index (BMI) 21.3 [19.2–24.3]
Less than or equal to 25 507 (78%)
Greater than 25 139 (22%)
Less than 18.5 121 (19%)
18.5–25 386 (60%)
Performance status (Karnofsky score) 97.9–5.2
a
aValue reported as mean–standard deviation (SD).
PREDICTORS OF SH AND LA IN BOTSWANA 761screening for the presence of SH/LA. Fourteen (12.6%) of the
111 screened participants were male, with the remainder
(n=97; 87.4%) being female. Twenty (19.8%) of these 111 pa-
tientshadatleastoneserumlactatelevelthatwasgreaterthan
twice the upper limits of normal (‡4.40 mmol/liter), and
therefore met our event deﬁnition. These 20 study partici-
pants having a deﬁned study event had a total of 74 serum
lactates drawn.
Of these 20 total screening events in which moderate to
severe serum lactate results (‡4.40 mmol/liter) were ob-
tained, 13 (65%) were classiﬁed as SH and 7 (35%) were di-
agnosed as LA (Table 2). All 20 (100%) were female. At
baseline, the median age was 37 years (IQR 32–45 years), the
median BMI was 28 (IQR 23–33), and the median time on
cART was 8.5 months (IQR 7.2–20.4 months). At the time of
their SH or LA event, these 20 patients had a median serum
lactate level of 5 (IQR 3–6 mmol/liter). Six (30%) of the 20
study participants experiencing an event died, with ﬁve of the
sixdeaths(83%)beingdeemedrelatedtoARVtreatment(four
lactic acidosis and one fulminant hepatic failure). One death
was unrelated to ARV treatment, as this patient died from
complications of active pulmonary tuberculosis (Table 2).
Four of the seven (57%) patients diagnosed with LA died as a
resultofthisacuteevent.Ofnote,allfourofthesepatientsalso
had a comorbid diagnosis of severe clinical pancreatitis
(hemorrhagic) with each having clinical symptoms (nausea,
vomiting, and/or abdominal pains) and grade 3/4 serum li-
pase elevations at the time of their demise. Three (75%) of the
four patients experiencing mortality as a result of their lactic
acidosis event had been receiving ‘‘D’’ drugs [namely, sta-
vudine (d4T), didanosine (ddI), or both] prior to their death,
with two having received d4T/3TC-based cART, one having
received ddI/ZDV-based cART, and the fourth having re-
ceived both ddI and d4T together as part of their second-line
(protease inhibitor-containing) regimen (Table 2). Four of the
seven (57%) patients diagnosed with LA also had a new di-
agnosis ofgrade2 orhigherperipheral neuropathy at thetime
their diagnosis of lactic acidosis was made.
Sex was a signiﬁcant predictor of SH/LA as 4.4% (20/
451) of females and 0% (0/199) of males had the event
(p<0.001, Fisher’s exact test). Among women, having a
higher baseline BMI was predictive for the development of
SH/LA (aHR=1.17 per 1-unit increase; 95% CI: 1.08–1.25,
p<0.0001) (Table 3).
Table 2. Characteristics of the 20 Female Study Participants at the Time of Event—Moderate
to Severe Symptomatic Hyperlactatemia (SH) or Lactic Acidosis (LA)
Pt Age
cART
regimen
Duration
of cART
(months)
CD4
+ cell
count
(cells/mm
3)
Weight
(kg) BMI
Lactate
level
(mmol/liter) Diagnosis Outcome
1 40 d4T, 3TC, EFV 6.8 234.1 91.5 31.9 6.5 LA/pancreatitis Died from related causes
2 46 d4T, 3TC, EFV 7.7 706.5 100.0 34.8 5.1 LA Survived
3 28 ZDV 3TC, EFV 7.7 112.3 62.0 23.7 4.9 SH Survived
4 33 d4T, 3TC, EFV 7.8 194.5 65.0 25.1 7.9 SH Survived
5 38 ZDV, 3TC, EFV 1.2 N/A 39.0 18.2 5.0 SH Died from unrelated
causes (pulmonary TB)
6 40 d4T, ddI, NFV 26.4 68.6 70.9 28.4 4.6 SH Survived
7 49 d4T, 3TC, NVP 6.3 241.8 96.0 34.8 7.0 SH Survived
8 54 d4T, 3TC, EFV 7.0 178.7 97.0 35.7 10.0 LA/pancreatitis Died from related causes
9 37 d4T, ddI, NFV 25.5 180.8 68.8 29.4 15.3 LA/pancreatitis Died from related causes
10 29 d4T, 3TC, NVP 0.6 202.0 57.5 29.7 7.9 SH Died from unrelated causes
(fulminant hepatic failure)
11 32 d4T, 3TC, NVP 9.0 534.0 92.6 33.2 5.1 SH Survived
12 46 d4T, 3TC, EFV 8.1 527.2 63.0 28.2 10.4 LA Survived
13 53 d4T, 3TC, EFV 10.0 225.9 79.9 29.7 5.2 SH Survived
14 35 ZDV, ddI. EFV 8.5 372.8 89.5 35.0 8.2 LA/pancreatitis Died from related causes
15 46 d4T, ddI, NVP 20.8 203.7 78.0 33.3 11.9 LA Survived
16 32 ZDV, ddI, EFV 23.0 374.0 95.0 40.1 6.0 SH Survived
17 45 ZDV, 3TC, EFV 15.4 287.0 84.0 30.9 6.9 SH Survived
18 36 ZDV, ddI, EFV 24.0 548.0 60.0 21.0 5.4 SH Survived
19 37 ZDV, 3TC, EFV 18.5 510.0 58.0 20.8 6.2 SH Survived
20 31 d4T, 3TC, NVP 23.0 479.0 54.0 23.4 4.7 SH Survived
ZDV, zidovudine; 3TC, lamuvidine; ddI, didanosine; d4T, stavudine; NVP, nevirapine; EFV, efavirenz; NFV, nelﬁnavir.
Table 3. Risk Factors for the Development of Moderate to Severe Symptomatic Hyperlactatemia (SH)
or Lactic Acidosis (LA) Among Female Study Participants (n=451)
Risk factor Adjusted hazard ratio (HR) 95% conﬁdence interval p-value
Age (per 10 year increase) aHR=0.65 [0.28–1.52] 0.33
BMI
a (per 1-unit increase) aHR=1.17 [1.08–1.25] <0.0001
aRisk factors signiﬁcantly associated (p<0.05) with the development of SH/LA.
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toms, (2) being ‘‘screened’’ for SH/LA due to symptoms but
lactate <4.4, or (3) SH/LA.Female sex and higher baseline BMI
were predictive of symptoms and/or the development of SH/
LA in these analyses [adjusted odds ratio (aOR)=2.11, 95% CI:
1.09–4.08, p=0.028; and 1.09, 95% CI: 1.04–1.14, p<0.001, re-
spectively]. Randomization to d4T/3TC-based cART (aOR=
1.76 relative to ZDV/3TC; 95% CI: 1.03–3.01, p=0.04) and
having a lower baseline hemoglobin (aOR=1.28 per 1-unit de-
crease; 95%; CI 1.1–1.49, p=0.002) were also predictive of
symptoms and/or the development of SH/LA (Table 4).
Subjects who survived their episode of SH or LA resumed
ART with a regimen that included one of the following dual
NRTI combinations (tenofovir/emtricitabine, tenofovir/la-
muvidine, abacavir/lamuvidine, or tenofovir/abacavir) plus
lopinavir/ritonavir (Kaletra or Aluvia when this heat-stable
formulation became available). All patients continued to have
plasma HIV-1 viral load levels below 400 copies/ml, along
with excellent immunologic recovery.
Discussion
Preliminary data from Botswana and South Africa have
shown that cART-treated adults have higher than expected
rates of lactic acidosis (1.0–1.1%) when compared to rates
previously described elsewhere.
10–15,19,23 There also appears to
be a strongassociation betweenthe riskfor this potentially life-
threateningtoxicityandsexandbodyhabitus,withoverweight
(BMI>25) females being at a signiﬁcantly higher risk for tox-
icity.
10–15,19,23 More in-depth studies are needed to further
elucidaterisk,asthestrongassociationwithfemalesexappears
to be largely driven by baseline body compositional differ-
ences; approximately 2.5 times more females (26.4% of females
compared to 10.1% of males) had baseline BMIs greater than
25. Host genetic predisposition may also contribute to these
distinct risk susceptibility differences, especially as risk for the
development of lactic acidosis has been previously associated
with genetic variation among those with inherited mitochon-
drialDNAdisorders[i.e.,mitochondrialencephalopathy,lactic
acidosis,andstroke(MELAS)syndromeandtheA3243Gpoint
mutation] as well as persons treated with other potentially
causative medications (i.e., the association between the mito-
chondrial DNA A2706G polymorphism and linezolid-induced
lactic acidosis and plasma lactate concentrations and SLC22A2
gene 808 G/T variants among metformin-treated adults).
24–26
Among urban Botswana cART-treated clinical trial partici-
pants, being female and overweight (i.e., having a higher base-
line BMI) were strongly predictive for the development of SH or
LA. As national care and treatment programs continue to ex-
pand in sub-Saharan Africa, it will be of paramount importance
to establish and maintain longitudinal toxicity registries in order
to monitor rates of these and other potentially life-threatening
toxicities (i.e., nevirapine cutaneous hypersensitivity and hepa-
totoxicity, as well as tenofovir-associated bone mineral density
abnormalities and renal toxicity). In the majority of sub-Saharan
African countries, proportionately more females are receiving
cART than men, even when accounting for the higher HIV-1
prevalence rates among women. In addition, as national pro-
grams scale up, higher proportions of cART-treated adults will
be receiving care at primary and secondary-level healthcare fa-
cilities, where limited laboratory capacity exists for obtaining
serum lactate levels. In such settings, until d4T prescription has
been fully phased out, the routine use of validated point-of-care
lactate devices for screening persons at risk for the development
of SH/LA warrants serious consideration.
Table 4. Risk Factors for the Symptoms and/or the Development of Moderate to Severe Symptomatic
Hyperlactatemia (SH) or Lactic Acidosis (LA) Among All Screened Study Participants (n=650)
Risk factor Adjusted hazard ratio (HR) 95% conﬁdence Interval p-value
NRTI backbone
ZDV/3TC
a 1.0 N/A N/A
ZDV/ddI 1.49 [0.87–2.55] 0.15
d4T/3TC
b 1.76 [1.03–3.01] 0.04
NNRTI backbone
EFV
a 1.0 N/A N/A
NVP 0.92 [0.60–1.41] 0.71
Adherence arm
SOC 1.0 N/A N/A
ComDOT 1.20 [0.78–1.83] 0.41
Sex
b
Female
b 2.11 [1.09–4.08] 0.028
Male
a 1.0 N/A N/A
Age (per 10 years) 0.93 [0.69–1.24] 0.60
BMI
b (per 1 unit increase) 1.09 [1.04–1.14] <0.001
CD4
+ cell count (per 100 cells/mm
3 increase) 0.93 [0.72–1.21] 0.58
Log plasma HIV-1 RNA (per 1.0 log unit increase) 1.001 [0.70–1.43] 0.99
Hemoglobin
b (per 1 unit (g/dl) decrease) 1.28 [1.1–1.49] 0.002
aReference group; for dual NRTI comparisons=zidovudine (ZDV) plus lamuvidine (3TC); for NNRTI comparisons=efavirenz (EFV); and
for sex comparisons=male.
bRisk factors signiﬁcantly associated (p<0.05) with the development of SH/LA.
ZDV, zidovudine; 3TC, lamuvidine; ddI, didanosine; d4T, stavudine; NVP, nevirapine; EFV, efavirenz; SOC, standard-of-care; ComDOT,
intensiﬁed adherence strategy, namely SOC plus community-based cART supervision; NRTI, nucleoside reverse transcriptase inhibitor;
NNRTI, nonnucleoside reverse transcriptase inhibitor.
PREDICTORS OF SH AND LA IN BOTSWANA 763One potentiallimitation includesthepossibility ofselection
bias, due to the fact that all patients experiencing an SH or LA
event were female. Of note, all 650 patients randomized to
receive cART in this clinical trial were intensively screened for
the presence of ARV-related toxicities, including the devel-
opment of lactic acidosis, as the development of a treatment-
modifying toxicity (speciﬁcally, theﬁrst incidence of a grade 3
or higher adverse event) was a primary outcome of the study.
The majority of patients (87.4%) undergoing additional
screening were female, speciﬁcally, the 111 having signs/
symptoms and/or laboratory abnormalities suggestive of
underlying lactic acidosis and having a serum lactate level
drawn. However, 14 males did have serum lactate levels
drawn, with similar proportions of them (as compared to fe-
males) having clinical sign/symptoms and/or laboratory
abnormalities as their triggering event, realizing that the
presence of one or more grade 3 or higher laboratory events
[SGPT (ALT), SGOT (AST), LDH; and/or serum bicarbonate
level less than 20.0 mmol/liter] was entirely nonsubjective,
i.e., meeting the threshold for additional screening based on
these protocol-mandated laboratory cutoff values was all
based on existing Division of AIDS toxicity/laboratory
grading scales, thus limiting the chance for selection bias in
this uniformly screened study population. Certainly, treating
study clinicians could have had ‘‘last-case’’ bias when
screening their next patient for the presence of lactic acidosis
based on the clinical and/or laboratory characteristics of the
patient they most recently cared for that did experience an
SH or LA event (i.e., being female and/or overweight). We
are also not able to compare SH/LA event rates among
overweight cART-treated females in our study to those not
receiving cART in our setting, as our team intensively moni-
tored clinical trial participants only once they initiated cART
(at the time of study enrollment/randomization).
In summary, being female and having a higher baseline
BMI are predictive for the development of SH/LA. Our re-
sults suggest thatd4T/3TC-basedcART andanemiamay also
be associated with the symptoms and/or the development of
SH/LA.In southern Africa, it maybe prudentnot toprescribe
d4T-based cART to ‘‘at-risk’’ patients. Additional studies in-
cluding an evaluation of host genetic factors are ongoing to
further elucidate this risk.
Acknowledgments
We would like to formally acknowledge the Botswana
Ministry of Health, the Princess Marina Hospital adminis-
tration, outpatient adult Infectious Disease Care Clinic
(IDCC), and inpatient Medical Ward teams, the entire Adult
Antiretroviral Treatment and Drug Resistance (Tshepo) study
team, and our funder, the Bristol-Myers Squibb foundation,
for their support of this research initiative. We also want to
formally acknowledge and thank all adult study participants.
The project described was also supported by the following
research grants from the National Institute of Allergy and In-
fectious Diseases: K23AI073141 (PI: C. William Wester, M.D.,
M.P.H.) grant evaluating Risk Factors for the Development of
Lactic Acidosis and Pancreatitis in Botswana and P30AI
060354 (PI: C. William Wester, M.D., M.P.H.), Harvard Center
for AIDS Research (CFAR) grant evaluating the Risk Factors
for the Development of Nevirapine-Associated Toxicity in
Southern Africa. The content is solely the responsibility of the
authorsanddoesnotnecessarily representtheofﬁcialviewsof
the National Institute of Allergy and Infectious Diseases or the
National Institutes of Health. In addition, we also formally
acknowledge the Vanderbilt-Meharry CFAR grant (Grant
P30AI54999)thatsupportedtheworkofVanderbiltUniversity
School of Medicine senior statistician Bryan E. Shepherd.
Author Disclosure Statement
No competing ﬁnancial interests exist.
References
1. Gilks CF, Crowley S, Ekpini R, et al.: The WHO public-health
approach to antiretroviral therapy against HIV in resource-
limited settings. Lancet 2006;368:505–510.
2. Idigbe EO, Adewole TA, Eisen G, et al.: Management of HIV-
1 infection with a combination of nevirapine, stavudine, and
lamuvidine: A preliminary report on the Nigerian anti-
retroviral program. J Acquir Immune Deﬁc Syndr 2005;40(1):
65–69.
3. Laurent C, Kouanfack C, Koulla-Shiro S, et al.: Effectiveness
and safety of a generic ﬁxed-dose combination of nevir-
apine, stavudine, and lamuvidine in HIV-1 infected adults in
Cameroon: Open-label multicentre trial. Lancet 2004;364:
29–34.
4. Carr A and Cooper DA: Adverse effects of antiretroviral
therapy. Lancet 2000;356:1423–1430.
5. Modica Napolitano JS: AZT causes tissue-speciﬁc inhibition
of mitochondrial bioenergetic function. Biochem Biophys
Res Commun 1993;194:170–174.
6. Brinkman K, ter Hofstede HJM, Burger DM, Smeitink JAM,
and Koopmans PP: Adverse effects of reverse transcriptase
inhibitors: Mitochondrial toxicity as a common pathway.
AIDS 1998;12:1735–1744.
7. Lewis W and Dalakas MC: Mitochondrial toxicity of anti-
viral drugs. Nat Med 1995;1:417–422.
8. Arenas-Pinto A, Grant AD, Edwards S, and Weller IV: Lactic
acidosis in HIV infected patients: A systematic review of
published cases. Sex Transm Infect 2003;79(4):340–343.
9. Falco V, Rodriguez D, Ribera E, et al.: Severe nucleoside-
associated lactic acidosis in human immunodeﬁciency virus-
infected patients: Report of 21 cases and review of the
literature. Clin Infect Dis 2002;34:838–846.
10. Bolhaar MG and Karstaedt AS: A high incidence of lactic
acidosis and symptomatic hyperlactatemia in women re-
ceiving highly active antiretroviral therapy in Soweto, South
Africa. Clin Infect Dis 2007;45(2):254–260.
11. Lactic Acidosis International Study Group: Risk factors for
lactic acidosis and severe hyperlactatemia in HIV-1 infected
adults exposed to antiretroviral therapy. AIDS 2007;21(18):
2455–2464.
12. Geddes R, Knight S, Moosa MY, Reddi A, Uebel K, and
Sunpath H: A high incidence of nucleoside reverse tran-
scriptase inhibitor (NRTI)-induced lactic acidosis in HIV-
infected patients in a South African context. S Afr Med J
2006;96(8):722–724.
13. Fabian J, Venter WD, Mkhabela L, Levin JB, Baker L, and
Naicker S: Symptomatic hyperlactatemia in adults on anti-
retroviral therapy: A single-centre experience. S Afr Med J
2008;98(10):795–800.
14. Osler M, Stead D, Rebe K, Meintjes G, and Boulle A: Risk
factors for and clinical characteristics of severe hyperlacta-
temia in patients receiving antiretroviral therapy: A case-
control study. HIV Med 2010;11(2):121–129.
764 WESTER ET AL.15. Matthews LT, Giddy J, Ghebremichael M, et al.: A risk-factor
guided approach to reducing lactic acidosis and hy-
perlactatemia in patients on antiretroviral therapy. PLoS
One 2011;6(4):e18736.
16. Marceau G, Sapin V, Jacomet C, et al.: Frequency, risk fac-
tors, and outcome of hyperlactatemia in HIV-positive per-
sons: Implications for the management of treated patients.
Clin Chem 2003;49(7):1154–1162.
17. Bonnet F, Balestre E, Bernardin E, et al.: Risk factors for
hyperlactatemia in HIV- infected patients, Aquitaine Cohort,
1999–2003. Antivir Chem Chemother 2005;16(1):63–67.
18. Boubaker K, Flepp M, Sudre P, et al.: Hyperlactatemia and
antiretroviral therapy: The Swiss HIV Cohort Study. Clin
Infect Dis 2001;33:1931–1937.
19. Wester CW, Okezie OA, Thomas AM, Bussmann H, Moyo S,
et al.: Higher than expected rates of lactic acidosis among
highly active antiretroviral therapy-treated women in Bots-
wana. J Acquired Immune Deﬁc Syndr 2007;46(3):318–322.
20. Wester CW, Thomas AM, Bussmann H, et al.: Non-nucleo-
side reverse transcriptase inhibitor outcomes among com-
bination antiretroviral therapy-treated adults in Botswana.
AIDS 2010;24(Suppl 1):S27–S36.
21. BotswanaNationalARVProgramme(‘‘MASA’’)press release/
circular dated September 2006, Vol. 20, Ministry of Health,
Botswana; with updated country-wide HAART statistics.
22. Botswana Guidelines on Antiretroviral Treatment: Ministry
of Health, Botswana. Anabwani G, Jimbo W (eds.); origi-
nally released 2002; revised and latest 2005 available in
January 2005.
23. Adult Clinical Trials Group (AACTG) website: AACTG
Toxicity Evaluation Group (TOX-EG) working reference
document from the AACTG website, with speciﬁc instruc-
tions for obtaining plasma lactate levels, dated July 23, 2002;
available at http:/ /aactg.s-3.com/; last accessed November
2010.
24. Fayssoil A: Heart diseases in mitochondrial encephalomyo-
pathy, lactic acidosis, and stroke syndrome. Congest Heart
Fail 2009;15(6):284–287.
25. Carson J, Cerda J, Chae JH, Hirano M, and Maggiore P:
Severe lactic associated with linezolid use in a patient with
the mitochondrial DNA A2706G polymorphism. Pharma-
cology 2007;27(5):771–774.
26. Li Q, Liu F, Zheng TS, Tang I, Lu HJ, and Jia WP: SLCC22A2
gene 808 G/T variant is related to plasma lactate concen-
tration in Chinese type 2 diabetics treated with metformin.
Acta Pharmacol Sin 2010;31(2):184–190.
Address correspondence to:
C. William Wester
Vanderbilt University School of Medicine
Department of Medicine
Division of Infectious Diseases
Vanderbilt Institute for Global Health (VIGH)
1161 21st Avenue South
A-2200, Medical Center North
Nashville, Tennessee 37232-2582
E-mail: william.wester@vanderbilt.edu
PREDICTORS OF SH AND LA IN BOTSWANA 765